Enzymotec Ltd. Announces an Extraordinary General Meeting of Shareholders to Approve Its Compensation Policy
21 May 2014 - 6:05AM
Enzymotec Ltd. (Nasdaq:ENZY) (the "Company"), today announced that
it will hold an Extraordinary General Meeting of Shareholders on
Thursday, June 26, 2014. The record date for shareholders entitled
to vote at the meeting is Tuesday, May 27, 2014.
The meeting is being called for the following purpose:
To approve a compensation policy for
directors and other office holders of the Company in accordance
with the requirements of the Israeli Companies Law, 5759-1999,
pursuant to which shareholder approval for the compensation policy
must be obtained within nine (9) months of the Company's initial
public offering;
Approval of the above proposal requires the affirmative vote of
the holders of a majority of the voting power represented at the
meeting in person or by proxy and voting on the proposal. In
addition, the approval of the proposal is subject to satisfaction
of one of the following additional voting requirements:
- the majority voted in favor of the proposal must include a
majority of the shares held by non-controlling shareholders who do
not have a personal interest in the approval of the proposal that
are voted at the meeting, excluding abstentions; or
- the total number of shares held by non-controlling,
disinterested shareholders (as described in the previous
bullet-point) voted against the proposal must not exceed two
percent (2%) of the aggregate voting rights in the Company.
The presence (in person or by proxy) of any two or
more shareholders holding, in the aggregate, at least 25% of the
voting rights in the Company constitute a quorum for purposes of
the meeting. In the absence of the requisite quorum of shareholders
at the meeting, the meeting will be adjourned to the same day in
the next week, at the same time and place, unless otherwise
determined at the meeting in accordance with the Company's articles
of association. At such adjourned meeting the presence of at least
two shareholders in person or by proxy (regardless of the voting
power represented by their shares) will constitute a quorum.
Additional Information and Where to Find
It
In connection with the meeting, the Company will
make available to its shareholders of record a proxy statement
describing the time and place, and other logistical information
related to the meeting, and the proposal to be voted upon at the
meeting, along with a proxy card enabling them to indicate their
vote on the proposal. The Company is also furnishing copies of the
proxy statement and proxy card to the Securities and Exchange
Commission, or SEC, in a Report of Foreign Private Issuer on Form
6-K, which may be obtained for free from the SEC's website at
www.sec.gov and will be available on the Company's website at
www.enzymotec.com.
About the Company
The Company is a leading global supplier of specialty
lipid-based products and solutions. The Company develops,
manufactures and markets innovative bio-active lipid ingredients,
as well as final products, based on sophisticated processes and
technologies.
For more information, visit www.enzymotec.com.
CONTACT: Press Contact:
Katie Turner, ICR
+646 277 1228
Katie.turner@icrinc.com
John Mills, ICR
+310 954 1105
John.mills@icrinc.com
ENZYMOTEC LTD. (NASDAQ:ENZY)
Historical Stock Chart
From Jun 2024 to Jul 2024
ENZYMOTEC LTD. (NASDAQ:ENZY)
Historical Stock Chart
From Jul 2023 to Jul 2024